AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2015
Mar 4, 2015
30583_dirs_2015-03-04_af2053b0-5b9d-4bb9-81cc-339907336ae0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2015-03-02
Reporting Person: Davis George Eric (SVP, General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-03-02 | Common Stock | M | 23000 | $26.49 | Acquired | 87246 | Direct |
| 2015-03-02 | Common Stock | S | 23000 | $108.3055 | Disposed | 64246 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-03-02 | Stock Option (right to buy) Common Stock | $26.49 | M | 20000 | Disposed | 2021-05-11 | Common Stock (23000) | Direct |
Footnotes
F1: The price in column 4 is an average weighted price. The price actually received ranged from $108.16 to $108.59. The issuing person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
F2: Original option grant vests 6/48ths on November 12, 2011 and 1/48th on the 12th day of every month thereafter
F3: Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.